Investor Presentaiton

Driving growth with strategic choices. sanofi DupixentⓇ Maximize patient benefits with ambition to achieve > €13bn peak sales across type 2 inflammatory diseases [COPD not included] €8.3bn sales in 2022, +43.8% 5 years after launch Vaccines Expected mid-to-high single-digit growth¹, through differentiated products, market expansion, launches Pipeline Prioritize and accelerate portfolio of potentially transformative therapies 6.3% growth in 2022 84 projects in clinical development DupixentⓇ® is a product in collaboration with Regeneron 1. Sales CAGR from 2018 base to 2025 5 Vaccines Investor Event

View entire presentation